Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the...

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means that there is,...

Arzerra® Approved as Maintenance Therapy for Advanced CLL

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not received prior...

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting,...

Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL)...